| Name | Title | Contact Details |
|---|
Capitol Christian Music Group is the worlds leading Christian Music company and market leader in recorded music, distribution, and music publishing. Part of Universal Musics Capitol Music Group, Capitol Christian Music Group operates several divisions including Capitol CMG Label Group (Sparrow Records, ForeFront Records, Credential Recordings, sixstepsrecords, Hillsong), EMI Gospel, Capitol Christian Distribution and Capitol CMG Publishing. Led by President and CEO Bill Hearn and a strong executive team of long-time Christian and Gospel music veterans, Capitol Christian Music Group is characterized by a strong commitment to artists and songwriters, one another, our customer and community service.
At the Gibraltar International Bank, we believe that empowering you to manage your money easily is key. We have invested in state-of-the-art technology and online banking so that you can conduct your banking in whatever situation you may find yourself. There really is so much that we can offer both personal and corporate clients. To discover what we can do for you, just get in touch using the details below. We would love to hear from you. Phone +350 (200) 13900 Email gibraltar@gibintbank.gi
Founded in Los Angeles in 2007, Cinesamples has grown to become an industry leader in the development of top virtual instruments and sample libraries. We are passionate about the sampling process, and you can hear our products in many films, tv shows, and video games.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.